NOVEL METHOD

There is provided inter alia according to the invention an ex vivo method of obtaining tolerogenic antigen presenting cells (APCs) that have the capability to induce tolerance in the immune system to an antigen, the method comprising (a) isolating monocytes from a sample obtained from a mammal; and...

Full description

Saved in:
Bibliographic Details
Main Authors ENGLEZOU, PAVLOS, POOL, LIENEKE, WIGREN, MARIA, ROMEDAHL, HANNE
Format Patent
LanguageEnglish
French
Published 17.06.2021
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:There is provided inter alia according to the invention an ex vivo method of obtaining tolerogenic antigen presenting cells (APCs) that have the capability to induce tolerance in the immune system to an antigen, the method comprising (a) isolating monocytes from a sample obtained from a mammal; and (b) culturing the isolated monocytes in a cell culture to induce differentiation of the monocytes into antigen presenting cells having a tolerogenic phenotype, wherein the cell culture comprises (i) retinoic acid and TGFbeta, (ii) retinoic acid, TGFbeta and an AhR agonist or (iii) retinoic acid and an AhR agonist. Entre autres, l'invention concerne un procédé ex vivo d'obtention de cellules présentatrices d'antigène tolérogènes (CPA) qui ont la capacité d'induire une tolérance dans le système immunitaire à un antigène, le procédé comprenant (a) l'isolement de monocytes à partir d'un échantillon obtenu à partir d'un mammifère ; et (b) la culture des monocytes isolés dans une culture cellulaire pour induire la différenciation des monocytes en cellules présentatrices d'antigène ayant un phénotype tolérogène, la culture cellulaire comprenant (i) l'acide rétinoïque et le TGFbeta , (ii) L'acide rétinoïque, le TGFbeta et un agoniste AhR ou (iii) l'acide rétinoïque et un agoniste AhR.
Bibliography:Application Number: CA20203163486